You are here

A Study to Evaluate Infants With Potential Exposure to Tanezumab Before Birth

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Tempe, Arizona, 85282 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Infant Developmental Assessment
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0-15
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

Subject is an infant born to a mother who was exposed to study drug on a tanezumab clinical
study through direct maternal exposure; or is an infant born to a mother who is a partner
of a male patient who was exposed to study drug in a tanezumab clinical study prior to or
around the time of conception and/or is exposed during his partner's pregnancy.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

There are no exclusion criteria for this study

NCT01362660
Pfizer
Completed
A Study to Evaluate Infants With Potential Exposure to Tanezumab Before Birth

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now